Ecosystem
Beta Site
Search Results
42 items found for "Ryan M Anderson"
- Leukotriene B4 receptor 2 governs macrophage migration during tissue inflammation
Authors Ebru Ermis , Titli Nargis , Kierstin Webster , Sarah A Tersey , Ryan M Anderson , Raghavendra
- Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
Authors Anna B Halpern , Eduardo Rodríguez-Arbolí , Megan Othus , Kelsey-Leigh A Garcia , Mary-Elizabeth M Percival , Ryan D Cassaday , Vivian G Oehler , Pamela S Becker , Jacob S Appelbaum , Janis L Abkowitz , Johnnie J Orozco , Siobán B Keel , Paul C Hendrie , Bart L Scott , M Cristina Ghiuzeli , Elihu H Estey
- Ep 82 with Dr. Lauren M. Slosky
Lauren M. Slosky About Dr. Lauren M. Lauren M.
- Removing the GPCR-mediated brake on exocytosis enhances insulin action, promotes adipocyte browning, and protects against diet-induced obesity
diet-induced obesity Date & Time Friday, November 3rd / 2:45 PM Abstract Coming Soon Authors and Affiliations Ryan Hamm, Ph.D. is the Aileen M.
- Identification of S1PR4 as an immune modulator for favorable prognosis in HNSCC through machine learning
to cladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) Comparing outcomes using CLAG-M/sorafenib with those of a matched cohort of 76 patients treated with CLAG-M alone, multivariable-adjusted survival estimates were improved for 41 patients receiving CLAG-M These data suggest that CLAG-M/sorafenib is safe and improves OS and EFS relative to CLAG-M alone, with
- Ep 103 with Dr Kathleen Caron
Kathleen Caron About Kathleen M. Caron Kathleen M. Caron, Ph.D. is the Frederik L. Kathleen M.
- The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
Authors Victoria H Wu , Bryan S Yung , Farhoud Faraji , Robert Saddawi-Konefka , Zhiyong Wang , Alexander T Wenzel , Miranda J Song , Meghana S Pagadala , Lauren M Clubb , Joshua Chiou , Sanju Sinha , Marin
- Protease-Activated Receptor-1 IgG Autoantibodies in Patients with COVID-19
Anne-Christin Beatrice Wilde, Pegah Ramezani Rad, Wolfgang Poller, Erik Asmus, Szandor Simmons, Wolfgang M Kuebler, Martin Witzenrath, Lajos Markó, Kai Jakobs, Marianna Puccini, David M Leistner, Ursula Rauch-Kröhnert
- Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19
Authors Florian Tran , Danielle M M Harris , Alena Scharmacher , Hanna Graßhoff , Kristina Sterner ,
- Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases
NGF , NMU , NP , Na(v) , Nasal polyps , Nerve growth factor , Neuromedin U , OSM , OSMRβ , Oncostatin M , Oncostatin-M specific receptor subunit beta , PAR2 , PC(20) , PN , Protease activated receptor 2 , potential , Transient receptor potential ankyrin 1 , Transient receptor potential cation channel subfamily M member 4 , Transient receptor potential cation channel subfamily M member 8 , Transient receptor potential
- Delivery of US28 by incoming HCMV particles rapidly attenuates Akt activity to suppress HCMV lytic replication in monocytes
Authors Jamil Mahmud, Brittany W Geiler, Juthi Biswas, Michael J Miller, Julia E Myers, Stephen M Matthews , Amanda B Wass, Christine M O'Connor, Gary C Chan Source Contribute to the GPCR News Coming soon Become
- Ep 14 with Dr. Bryan Roth
Bryan Roth About this episode Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Bryan leads a $26.9 Million project to create better psychiatric medications, among other things. Join me and learn more about Bryan and his work. Dr. Bryan Roth on the web UNC School of Medicine / Pharmacology Roth Lab Roth Leads $26.9 Million Project
- Identification of a G-protein coupled receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis
The predictive ability of the model was evaluated by Kaplan-Meier (K-M) survival analysis. K-M analysis of the prognostic model showed that it could differentiate high- and low-risk patients,
- G protein-coupled estrogen receptor (GPER)/GPR30 forms a complex with the β1-adrenergic receptor, a membrane-associated guanylate kinase (MAGUK) scaffold protein, and protein kinase A anchoring protein (AKAP) 5 in MCF7 breast cancer cells
Authors Julia Tutzauer , D Stephen Serafin , Tobias Schmidt , Björn Olde , Kathleen M Caron , L M Fredrik
- Ep 75 with Vaithish Velazhahan
mechanisms of flavonoids in cancer using nuclear magnetic resonance spectroscopy (NMR) led to a Barry M.
- Session VI | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Authors & Affiliations "Groff, Karenna; Donaldson, Hayley; Anderson, Sebastian; Pitti, Kiran; Wang, Shuai Tina M. Iverson. I then pursued a postdoctoral research position under the mentorship of Dr.
- Chemokine N-terminal-derived peptides differentially regulate signaling by the receptors CCR1 and CCR5
Walser , Stavroula Louka , Ida Aaberg Lillethorup , Jon Våbenø , Katrine Qvortrup , Paul Proost , Mette M
- Interaction with the cell adhesion molecule NEGR1 affects mGluR5 cell signalling
signalling Date & Time Friday, November 3rd / 1:30 PM Abstract Coming Soon About Fabiola Ribeiro "Fabiola M.
- Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors
Authors Bongers B J , Gorostiola González M , Wang X , van Vlijmen HWT , Jespers W , Gutiérrez-de-Terán
- Blockade of vasoactive intestinal peptide receptor 2 (VIPR2) signaling suppresses cyclin D1-dependent cell-cycle progression in MCF-7 cells
The percentage of cells in the S-M phase was decreased in MCF-7 cells treated with KS-133.
- In Silico Design of Novel RGS2-Galpha-q Interaction Inhibitors with Anticancer Activity
Bair, Natalie Printy, So Hee Choi, Joshua Wilkinson, Joseph O'Brien, Brian Myers, David Roman, Tarek M
- Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion
Qiaoying Wang , Edward Philip Carter , Nicolas Jaime Roth , Jessica Gibson , Ariana Samadi , Hemant M
- "Have a nice weekend, and I'll see you tomorrow!": RAMP-interacting GPCR Pathways
Time Thursday, November 2nd / 4:30 PM Keynote Talk Abstract Coming Soon About Kathleen Caron "Kathleen M.
- Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling
Authors Sydney A Pascetta , Sarah M Kirsh , Makenna Cameron , James Uniacke .
- Identification of Small-Molecule Antagonists Targeting the Growth Hormone Releasing Hormone Receptor (GHRHR)
Panagiotopoulos, Robin du Preez, Michail Papadourakis, Konstantinos Tsianakas, Robert P Millar, Ross C Anderson
- Distinct Activation Mechanisms of CXCR4 and ACKR3 Revealed by Single-Molecule Analysis of their Conformational Landscapes
Authors Christopher T Schafer, Raymond F Pauszek 3rd, Martin Gustavsson, Tracy M Handel, David P Millar
- Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways
Authors Xin Miao , Gilbert Koch , Shichen Shen , Xue Wang , Jun Li , Xiaomeng Shen , Jun Qu , Robert M
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
Croucher , Maya Ridinger , Pamela S Becker , Tara L Lin , Sandra L Silberman , Eunice S Wang , Amer M
